Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGLS8429 SAD study in healthy volunteers
NCT05429073Phase 1Completed
- Sponsor
- Regulus Therapeutics
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of farabursen in autosomal dominant polycystic kidney disease (ADPKD) (4 cohorts), sponsored by Regulus Therapeutics. Primary endpoint: Incidence of Adverse Events. Started Jun 2022; status: completed.
02
Drugs
farabursen
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT05429073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429073.